<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:422aba44-214c-4cb0-8987-b76f3b4cc510,g:c0e9165d-3bfe-42fb-9b44-57f79fe0928d,d:413b9a7fd6bb48a590995fc856c9da56--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>angn-20220330</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl80L2ZyYWc6ZGVkNGNhZjNjNTU1NGZkY2FlMTA3ZTBkZjhkNGFkZjgvdGFibGU6OGI4NDQzMDBmM2I2NDhmMTlkOGVkODM5OTEyNDRiNGYvdGFibGVyYW5nZTo4Yjg0NDMwMGYzYjY0OGYxOWQ4ZWQ4Mzk5MTI0NGI0Zl8yLTEtMS0xLTQxNTA4_cf4f5065-4c56-4a60-ab9b-7b94faec3641">0001601485</ix:nonNumeric><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl80L2ZyYWc6ZGVkNGNhZjNjNTU1NGZkY2FlMTA3ZTBkZjhkNGFkZjgvdGFibGU6OGI4NDQzMDBmM2I2NDhmMTlkOGVkODM5OTEyNDRiNGYvdGFibGVyYW5nZTo4Yjg0NDMwMGYzYjY0OGYxOWQ4ZWQ4Mzk5MTI0NGI0Zl81LTEtMS0xLTQxNTA4_f99b1e71-3ac7-4f33-8d3f-f4a20cfd1ebe">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="angn-20220330.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-30</xbrli:startDate><xbrli:endDate>2022-03-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i413b9a7fd6bb48a590995fc856c9da56_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNTc3_628cb8a5-4b66-42e9-ace8-35a877e2d40e">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNzc_17434f44-1d8d-47a6-8361-4ba61f84808f">March 30, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:21.5pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNTgx_70d00a79-87b1-4bd5-8d48-dc895a393ff5">ANGION BIOMEDICA CORP.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6MmIzMDExMmM1ZTRjNDFmZDlmY2IxMzczZTUzN2QyNDEvdGFibGVyYW5nZToyYjMwMTEyYzVlNGM0MWZkOWZjYjEzNzNlNTM3ZDI0MV8wLTAtMS0xLTQxNTA4_db1dd7e6-c915-4a2e-ae91-b6d6a1772f5f">Delaware</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6MmIzMDExMmM1ZTRjNDFmZDlmY2IxMzczZTUzN2QyNDEvdGFibGVyYW5nZToyYjMwMTEyYzVlNGM0MWZkOWZjYjEzNzNlNTM3ZDI0MV8wLTEtMS0xLTQxNTA4_42458708-5178-4d8a-824e-cc6a559e40c5">001-39990</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6MmIzMDExMmM1ZTRjNDFmZDlmY2IxMzczZTUzN2QyNDEvdGFibGVyYW5nZToyYjMwMTEyYzVlNGM0MWZkOWZjYjEzNzNlNTM3ZDI0MV8wLTMtMS0xLTQxNTA4_015b605d-2832-4dba-ab82-1ba71f98dd5a">11-3430072</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6MmIzMDExMmM1ZTRjNDFmZDlmY2IxMzczZTUzN2QyNDEvdGFibGVyYW5nZToyYjMwMTEyYzVlNGM0MWZkOWZjYjEzNzNlNTM3ZDI0MV8zLTAtMS0xLTQxNTA4_2f65ab48-fd71-4ca7-be42-2a5db9586c2e">51 Charles Lindbergh Boulevard</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6MmIzMDExMmM1ZTRjNDFmZDlmY2IxMzczZTUzN2QyNDEvdGFibGVyYW5nZToyYjMwMTEyYzVlNGM0MWZkOWZjYjEzNzNlNTM3ZDI0MV8zLTEtMS0xLTQxNTA4_ff961320-1ef5-44df-a39c-17a7848e349b">Uniondale</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6MmIzMDExMmM1ZTRjNDFmZDlmY2IxMzczZTUzN2QyNDEvdGFibGVyYW5nZToyYjMwMTEyYzVlNGM0MWZkOWZjYjEzNzNlNTM3ZDI0MV8zLTItMS0xLTQxNTA4_68abf5b7-55d4-47d0-96ea-18f83fe6aa8f">New York</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6MmIzMDExMmM1ZTRjNDFmZDlmY2IxMzczZTUzN2QyNDEvdGFibGVyYW5nZToyYjMwMTEyYzVlNGM0MWZkOWZjYjEzNzNlNTM3ZDI0MV8zLTMtMS0xLTQxNTA4_2f363b92-4979-4980-9ed1-8273fbf93c51">11553</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNTc5_83490356-4a7b-4088-ad4f-26c56d8381a7">415</ix:nonNumeric>) <ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNTgy_c66e2b0f-01b5-4896-80c4-a5ac8cce2342">655-4899</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNTcy_0554f2f5-8d8b-48fa-b611-d84435bfa91e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNTcz_1e791b1a-f43b-46f3-9152-ca624715a18d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNTc0_dbf2fd93-574a-46aa-a09a-40a5c49dee3a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNTc1_6fba216c-24f2-40b1-b7db-c4a9a7576505">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6YzU2OTQyMDE4ZDY1NDdjOTgxNjA5ODU1YWM3MTA5MTIvdGFibGVyYW5nZTpjNTY5NDIwMThkNjU0N2M5ODE2MDk4NTVhYzcxMDkxMl8xLTAtMS0xLTQxNTA4_1e95c7f1-73d5-4a5e-a0a4-7126d4e98d86">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6YzU2OTQyMDE4ZDY1NDdjOTgxNjA5ODU1YWM3MTA5MTIvdGFibGVyYW5nZTpjNTY5NDIwMThkNjU0N2M5ODE2MDk4NTVhYzcxMDkxMl8xLTEtMS0xLTQxNTA4_cf5bad47-4a70-41ed-82f5-6ff33a825181">ANGN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGFibGU6YzU2OTQyMDE4ZDY1NDdjOTgxNjA5ODU1YWM3MTA5MTIvdGFibGVyYW5nZTpjNTY5NDIwMThkNjU0N2M5ODE2MDk4NTVhYzcxMDkxMl8xLTItMS0xLTQxNTA4_0c9a91d8-42bc-4947-ba68-c7ce676078e4">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:right"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xMzEx_1045a3d2-3ee8-4f48-a409-e49a143e1e29">&#9746;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb5e7f19bd4b4c70b4ac8e44c4b02d86_D20220330-20220330" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQxM2I5YTdmZDZiYjQ4YTU5MDk5NWZjODU2YzlkYTU2L3NlYzo0MTNiOWE3ZmQ2YmI0OGE1OTA5OTVmYzg1NmM5ZGE1Nl8xL2ZyYWc6OWI0ZWU3M2ViMjczNDA4ZWEwNWJjZjcwZWQzNWFkMmQvdGV4dHJlZ2lvbjo5YjRlZTczZWIyNzM0MDhlYTA1YmNmNzBlZDM1YWQyZF8xNTgw_cacb942f-d157-4993-9084-907eaa6524b5">o</ix:nonNumeric></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i413b9a7fd6bb48a590995fc856c9da56_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">March&#160;30, 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Angion Biomedica Corp., a Delaware corporation (the &#8220;Company&#8221;), issued a press release announcing the Company&#8217;s financial results for the fiscal quarter and full year ended December 31, 2021. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.</span></div><div><span><br/></span></div><div id="i413b9a7fd6bb48a590995fc856c9da56_13"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.106%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit <br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit <br/>Description</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ex991_123121-8k.htm">Press release dated March 30, 2022 relating to the financial results for the year ended December 31, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div id="i413b9a7fd6bb48a590995fc856c9da56_16"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANGION BIOMEDICA CORP.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ JAY R. VENKATESAN, M.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">March&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jay R. Venkatesan, M.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">President and Chief Executive Officer and Chairman</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "angn-20220330.htm", "description": "8-K", "secsgml_size_bytes": 35416}]
{"company-data": {"conformed-name": "Angion Biomedica Corp.", "cik": "0001601485", "assigned-sic": "2834", "irs-number": "113430072", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39990", "film-number": "22787245"}, "business-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553", "phone": "(415) 655-4899"}, "mail-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553"}}
angn-20220330
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
March 30, 2022
Date of Report (date of earliest event reported)
ANGION BIOMEDICA CORP.
(Exact name of registrant as specified in its charter)
Delaware
001-39990
11-3430072
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
51 Charles Lindbergh Boulevard
Uniondale
New York
11553
(Address of Principal Executive Offices)
(Zip Code)
(
415
)
655-4899
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
ANGN
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 2.02 Results of Operations and Financial Condition
On
March 30, 2022
, Angion Biomedica Corp., a Delaware corporation (the "Company"), issued a press release announcing the Company's financial results for the fiscal quarter and full year ended December 31, 2021. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
Number
Exhibit
Description
99.1
Press release dated March 30, 2022 relating to the financial results for the year ended December 31, 2021.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANGION BIOMEDICA CORP.
By:
/s/ JAY R. VENKATESAN, M.D.
Date:
March 30, 2022
Jay R. Venkatesan, M.D.
President and Chief Executive Officer and Chairman